



**Uscom**

## ASX MEDIA RELEASE

---

### Uscom Partners with A&D for BP+ New Advanced Modules

**SYDNEY, Australia, Thursday 30<sup>th</sup> April 2020:** Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today announced the signing of a development and supply agreement with A&D Limited of Japan. The agreement relates to new technology being installed in the patented protected Uscom BP+ central blood pressure monitor. This supply agreement comes as the BP+ approaches regulatory approval in China and the US, and as Uscom transitions to volume manufacturing to meet the anticipated increased BP+ demand. The A&D module will be included in all new BP+ devices.

The BP+ advanced central blood pressure (BP) monitor and its stand alone software, the BP+ Reporter, provides new information to improve diagnosis and management of hypertension and vascular health. The non-invasive device provides information previously requiring invasive cardiac catheterisation, and measures more than 26 parameters of BP and generates three discrete pulse pressure wave forms from various locations in the circulation, including the aorta as the blood exits the heart and represents the most advanced technology of its kind.

Hypertension occurs in approximately 40% of all people over the age of 25 and is responsible for approximately 7.5m deaths annually from the associated complications of stroke, heart attack and kidney failure. Hypertension is one of the most preventable causes of disease, however its management depends on accurate diagnosis and precise application of therapy. However simple home care BP devices measuring BP in the arm are relatively ineffective, with less than 20% of all patients with hypertension having controlled BP. The BP+ has been nearly 10 years in R&D, and the clinical utility of this new technology continues to be defined across a number of important international studies with some of the world's leading clinicians and technology companies. Uscom has been working with A&D for 12 months on the development and refinement of precision components for the Uscom BP+.

A&D (Analogue and Digital) are a Tokyo based multinational company engaged in the development, manufacture and sale of precision measurement instruments in the Industrial and Medical and Health care sector. A&D was founded in 1977, and reported an annual revenue of ~\$600m AUD in 2018, of which approximately 1/3<sup>rd</sup> was from the Medical and Health care sector, and it was capitalised at a value of ~\$15B AUD on the Tokyo Stock Exchange.

Executive Chairman of Uscom, Associate Professor Rob Phillips said *"Current hypertensive management is poor, and we have developed the BP+ to advance the science in this common and dangerous condition. Quality technology is critical for our devices, and this new partnership with A&D, world leaders in medical measurements and instrumentation, allows Uscom to provide clinicians with the best tools for BP monitoring and hypertensive care. These technologic co-developments have been in testing for 12 months and are now central to the new BP+ devices. Uscom's philosophy is that improved clinical care will be driven by the implementation of advanced life-saving medical devices, and this is why BP+ is important."*

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases. The USCOM 1A provides vital guidance for optimising management of sepsis and the administration of fluid, inotropes and vasoactive therapies in critical care monitoring. The BP+ SpiroSonic devices improve diagnosis and management of hypertension, heart failure, asthma, COPD and sleep disorders in the clinical and home care environments.

#### References:

<https://www.who.int/news-room/fact-sheets/detail/hypertension>

[https://www.who.int/gho/ncd/risk\\_factors/blood\\_pressure\\_prevalence\\_text/en/](https://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/)



**Uscom**

## ASX MEDIA RELEASE

---

### About Uscom

**Uscom Limited (UCM):** An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

**The USCOM 1A:** A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

**The Uscom BP+:** A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

**Uscom SpiroSonic digital multi-path ultrasonic spirometers:** High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary **SpiroReporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse spirometry outputs and generate summary reports.

For more information, please visit: [www.uscom.com.au](http://www.uscom.com.au)

### Uscom Contacts

Rob Phillips  
Executive Chairman  
[rob@uscom.com.au](mailto:rob@uscom.com.au)

Brett Crowley  
Company Secretary